Warning
Mae'r hysbyseb swydd hon wedi dod i ben ac mae'r ceisiadau wedi cau.
Gene Therapy Research Nurse | Oxford University Hospitals NHS Foundation Trust
| Dyddiad hysbysebu: | 05 Mehefin 2024 |
|---|---|
| Cyflog: | Heb ei nodi |
| Gwybodaeth ychwanegol am y cyflog: | £35,392 - £42,618 Per annum pro rata |
| Oriau: | Llawn Amser |
| Dyddiad cau: | 05 Gorffennaf 2024 |
| Lleoliad: | Oxford, OX3 9DU |
| Cwmni: | Oxford University Hospitals NHS Foundation Trust |
| Math o swydd: | Cytundeb |
| Cyfeirnod swydd: | 6330956/321-NOTSS-6330956-B6 |
Crynodeb
Due to the increasing workload with the onset of new Gene Therapy (GT) trials we are looking for a Research Nurse to work alongside the existing team. We collaborate with biopharmaceutical companies, one of which focus’ the development of therapies for inherited retinal dystrophies. One of the Company’s lead programmes is a retinal gene therapy for Retinitis Pigmentosa (RP), a rare inherited cause of blindness that affects around 1 in 50,000 people. Gene therapy treatment has the potential to deliver a one-time treatment for RP and a range of other retinal dystrophies. Other GT trials include Wet Age-Related Macular Degeneration (AMD) and Stargardts disease.
We are looking for a dynamic Ophthalmic Research Nurse to work on various Gene Therapy related clinical trials. Working alongside an existing support team. Research experience is essential with knowledge of gene therapy & ophthalmology a bonus.
· The main objective for this Gene therapy Research Nurse role is to assist in the management of the gene therapy research portfolio of the Eye Research Group Oxford department, supporting the Clinical Lead for the gene therapy programmes. Ensuring that the trials run smoothly for the participants recruited.
· The post-holder will work with the gene therapy cohort of Ophthalmology patients with the Principal Investigator, and trial co-ordinator ensuring each gene therapy study is efficiently run, meeting recruitment targets.
• Actively recruiting identified patients and running protocol related procedures relative to the role.
Oxford University Hospitals NHS Foundation Trust is one of the largest NHS teaching trusts in the country. It provides a wide range of general and specialist clinical services and is a base for medical education, training and research.
The Trust comprises four hospitals - the John Radcliffe Hospital, Churchill Hospital and Nuffield Orthopaedic Centre in Headington and the Horton General Hospital in Banbury.
Our values, standards and behaviours define the quality of clinical care we offer and the professional relationships we make with our patients, colleagues and the wider community. We call this Delivering Compassionate Excellence and its focus is on our values of compassion, respect, learning, delivery, improvement and excellence. These values put patients at the heart of what we do and underpin the quality healthcare we would like for ourselves or a member of our family. Watch how we set out to deliver compassionate excellence via the OUH YouTube channel.
· The main objective for this Gene therapy Research Nurse role is to assist in the management of the gene therapy research portfolio of the Eye Research Group Oxford department, supporting the Clinical Lead for the gene therapy programmes. Ensuring that the trials run smoothly for the participants recruited.
· The post-holder will work with the gene therapy cohort of Ophthalmology patients with the Principal Investigator, and trial co-ordinator ensuring each gene therapy study is efficiently run, meeting recruitment targets.
• Liaison with the Principal Investigators, Research Co-ordinator and relevant team members to implement protocols ensuring that study specific investigations are carried out correctly and in a timely manner.
• Be responsible and competent in the extended skills necessary to this role for example: Phlebotomy including the coordination and collection of blood samples for Biomarker and PK. Intravenous cannulation (for Flourescein Angiography / Indocyanine green), and emergency care skills as appropriate e.g management of anaphylaxis.
This advert closes on Wednesday 19 Jun 2024